America Invents Act receives cautious welcome

@article{Fox2011AmericaIA,
  title={America Invents Act receives cautious welcome},
  author={J. Lawrence Fox},
  journal={Nature Biotechnology},
  year={2011},
  volume={29},
  pages={953-954}
}
  • J. Fox
  • Published 8 November 2011
  • Medicine, Biology
  • Nature Biotechnology
President Barack Obama signed the America Invents Act into law on September 16, praising it as a “much-needed reform,” calling it “the most significant reform of the Patent Act since 1952” and predicting that it “will speed up the patent process so that innovators and entrepreneurs can turn a new invention into a business as quickly as possible.” Amid widespread praise, some critics dispute those optimistic claims, saying that the new law might instead stifle university researchers and… 
Biotech patents surge from institutions off the beaten track
TLDR
Patents are more specific now, and more patents are now being filed closer to when inventions are disclosed, and the America Invents Act shifted the US patent system from first to invent to first to file.
Recent trends of technology transfer in US universities with comparison to those following Bayh-Dole Act
Patents and licenses are foundational to successful technology transfer. In this article, the activities and performance of university patenting and licensing are studied to gauge the effectiveness
Startups, inventors cheer European unified patent
  • N. Moran
  • Biology, Medicine
    Nature Biotechnology
  • 2013
TLDR
Exelixis launched its first drug, the oral tyrosine kinase inhibitor Cometriq (cabozantinib), for treating patients with metastatic medullary thyroid cancer, after US Food and Drug Administration approval on November 29, with estimates that it could garner peak global sales in this indication of $300–500 million.
Performances of Technology Transfer Activities of US Universities after Bayh-Dole Act
 Abstract—The activities and performance of university patenting and licensing are studied to gauge the effectiveness of the Bayh-Dole Act, which is the most influential pieces of US legislation on
Performance Assessments of Technology Transfer Offices of Thirty Major US Research Universities in 2012/2013
The activities and performance of thirty major universities technology transfer offices (TTOs) selected from major US universities are quantitatively assessed and compared. Six leading metrics,
Positive signals from Washington
  • J. Fox
  • Biology, Medicine
    Nature Biotechnology
  • 2012
US biotech seems reenergized, but unsettled policy questions take a back seat to pending national elections, particularly with the presidency at stake. Jeffrey L Fox reports.

References

SHOWING 1-2 OF 2 REFERENCES
Myriad decision reassures biotechs but diagnostics still murky
TLDR
Though the ruling gives cDNA patents a thumbs up, using DNA sequences as diagnostics is mired in uncertainty and the next generation of products is less likely to be based on gene patents than on more nuanced and abstract approaches.
US court bolsters biotech patent protection